Devya Khaim Chandani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Devya Khaim Chandani has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Erum Siddiqui
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication Hafiz Waqas Naseer
Allama Iqbal Medical College, Punjab, Pakistan
1 shared publication- Humayou Ahmed
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication Maliha Khalid
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication- Muhammad Saad Khan
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Muhammad Tarish Abro
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication
Latest Publications
- 4 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Linaclotide in Pediatric Patients of Functional Constipation: A Meta-analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy and safety of linaclotide in children with functional constipation (FC) by synthesizing evidence from randomized controlled trials (RCTs). Data Sources: A systematic search of PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Google Scholar was conducted from inception through December 2024. The protocol was registered in PROSPERO (CRD420251018285), and the review was performed according to PRISMA guidelines. Study Selection and Data Extraction: RCTs comparing linaclotide with placebo in children (P = .0001) and reduction in straining (MD = −0.26, 95% CI, −0.42 to −0.10; P = .001). No significant effects were observed for spontaneous bowel movement frequency, complete spontaneous bowel movement frequency, or abdominal pain. Treatment-related adverse events were more frequent with linaclotide (relative risk [RR] = 2.93, 95% CI, 1.27-6.77), mainly due to increased diarrhea (RR = 3.81, 95% CI, 1.48-9.82). Relevance to Patient Care and Clinical Practice: Linaclotide may provide symptom relief for selected children with FC, particularly those with hard stools and straining despite conventional therapy. Clinicians should counsel families regarding diarrhea risk and monitor tolerability, while recognizing the limited long-term pediatric evidence. Conclusions: Linaclotide improves stool consistency and reduces straining in pediatric FC but does not consistently improve bowel frequency or global symptom resolution. Its safety profile is generally acceptable, although diarrhea is a notable adverse effect. Further long-term, independently funded trials are needed to define its optimal role in clinical practice.
- 4 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Linaclotide in Pediatric Patients of Functional Constipation: A Meta-analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy and safety of linaclotide in children with functional constipation (FC) by synthesizing evidence from randomized controlled trials (RCTs). Data Sources: A systematic search of PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Google Scholar was conducted from inception through December 2024. The protocol was registered in PROSPERO (CRD420251018285), and the review was performed according to PRISMA guidelines. Study Selection and Data Extraction: RCTs comparing linaclotide with placebo in children (P = .0001) and reduction in straining (MD = −0.26, 95% CI, −0.42 to −0.10; P = .001). No significant effects were observed for spontaneous bowel movement frequency, complete spontaneous bowel movement frequency, or abdominal pain. Treatment-related adverse events were more frequent with linaclotide (relative risk [RR] = 2.93, 95% CI, 1.27-6.77), mainly due to increased diarrhea (RR = 3.81, 95% CI, 1.48-9.82). Relevance to Patient Care and Clinical Practice: Linaclotide may provide symptom relief for selected children with FC, particularly those with hard stools and straining despite conventional therapy. Clinicians should counsel families regarding diarrhea risk and monitor tolerability, while recognizing the limited long-term pediatric evidence. Conclusions: Linaclotide improves stool consistency and reduces straining in pediatric FC but does not consistently improve bowel frequency or global symptom resolution. Its safety profile is generally acceptable, although diarrhea is a notable adverse effect. Further long-term, independently funded trials are needed to define its optimal role in clinical practice.